Tandem Diabetes Care Inc. (NASDAQ:TNDM) shares traded up 4.2% on Tuesday . The stock traded as high as $7.99 and last traded at $7.93, with a volume of 116,038 shares traded. The stock had previously closed at $7.61.

A number of research analysts have weighed in on TNDM shares. Zacks Investment Research upgraded shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $9.25 target price on the stock in a research note on Wednesday, May 4th. Robert W. Baird reiterated a “buy” rating on shares of Tandem Diabetes Care in a research note on Monday, May 2nd. Piper Jaffray Cos. reiterated a “buy” rating and issued a $12.00 target price on shares of Tandem Diabetes Care in a research note on Thursday, April 21st. Sterne Agee CRT reiterated a “neutral” rating on shares of Tandem Diabetes Care in a research note on Monday, May 16th. Finally, Wedbush reiterated an “outperform” rating and issued a $20.00 target price on shares of Tandem Diabetes Care in a research note on Wednesday, June 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. Tandem Diabetes Care presently has a consensus rating of “Buy” and an average price target of $14.21.

The stock’s 50 day moving average is $7.53 and its 200-day moving average is $8.22. The firm’s market cap is $237.65 million.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Thursday, April 28th. The medical device company reported ($0.68) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.01. The company earned $20.06 million during the quarter, compared to analysts’ expectations of $17.67 million. The company’s revenue for the quarter was up 63.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.83) EPS. On average, equities research analysts expect that Tandem Diabetes Care Inc. will post ($2.16) EPS for the current year.

A hedge fund recently raised its stake in Tandem Diabetes Care stock. Westfield Capital Management Co. LP increased its stake in Tandem Diabetes Care Inc. (NASDAQ:TNDM) by 3.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,125,281 shares of the medical device company’s stock after buying an additional 35,680 shares during the period. Westfield Capital Management Co. LP owned approximately 3.74% of Tandem Diabetes Care worth $13,290,000 at the end of the most recent quarter.

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.